Eli Lilly downgrades after underwhelming report, though diabetes business advances

The US-based pharmaceutical firm has adjusted its earnings per share forecast following a quarter with fewer sales than analysts had expected.


On Thursday, Eli Lilly publicized its second quarter figures for 2022 alongside a guidance downgrade containing a revised expectation for its earnings per share to USD 7.9–8.05 from a previous USD 8.15–8.3.

The previous prognosis did not hold water due to currency headwinds, but the company’s sales guidance is being maintained due to additional sales of Covid-19 treatment bebtelovimab.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs